XTRA:RHM
XTRA:RHMAerospace & Defense

Rheinmetall (XTRA:RHM) Valuation Check After Rising Investor Focus On European Defense Spending

Why recent geopolitical tension matters for Rheinmetall shares President Trump’s intervention in Venezuela has sharpened concerns about global security, drawing fresh investor attention to defense contractors. Rheinmetall (XTRA:RHM), closely linked to Europe’s military spending ambitions, recently saw its share price move 7% higher on this backdrop. See our latest analysis for Rheinmetall. For context, Rheinmetall’s recent 1-day share price return of 9.36% and 7-day return of 14.81% come...
XTRA:DTE
XTRA:DTETelecom

A Look At Deutsche Telekom (XTRA:DTE) Valuation As New 2026 Share Buy-Back Plan Is Announced

New buy-back program puts Deutsche Telekom’s capital return in focus Deutsche Telekom (XTRA:DTE) has launched a fresh share buy-back program for 2026 after completing its 2025 effort, putting the company’s capital return policy and share count trends back in the spotlight for investors. The 2025 program involved repurchasing about 65.4 million shares, around 1.3% of the share capital. For 2026, the Board has approved up to €2b of buy-backs running from January 5 through year end. Management...
XTRA:EVT
XTRA:EVTLife Sciences

Evotec (XTRA:EVT) Valuation Check After Recent Share Price Weakness And AI Platform Growth Hopes

Evotec stock: recent performance snapshot Evotec (XTRA:EVT) has drawn attention after a difficult past 3 months, with the share price showing a negative total return and a similar pattern over the past year, prompting closer scrutiny from investors. See our latest analysis for Evotec. At a share price of €5.51, Evotec has seen short term momentum cool. A 90 day share price return of an 18.71% decline sits alongside a 1 year total shareholder return showing a 35.44% loss. This points to fading...
XTRA:ENR
XTRA:ENRElectrical

Siemens Energy (XTRA:ENR) Valuation Check As Remote Operations Centers Reshape Power Plant Efficiency

Remote operations shift puts Siemens Energy (XTRA:ENR) in focus Recent coverage of Siemens Energy’s rollout of Remote Operations Centers, built around its Omnivise software platform, has drawn attention to how the company is centralizing power plant monitoring and predictive maintenance. See our latest analysis for Siemens Energy. The Remote Operations Center rollout arrives after a strong run in the shares, with a 90 day share price return of 21.59% and a very large 3 year total shareholder...
XTRA:FTK
XTRA:FTKCapital Markets

Will flatexDEGIRO’s Shift to an SE Structure and New COO Recast flatexDEGIRO's (XTRA:FTK) Narrative

In late December 2025, flatexDEGIRO changed its legal form and that of flatexDEGIRO Bank from a German stock corporation (AG) to a Societas Europaea (SE), while also expanding its Group Management Board and appointing long-serving executive Jens Möbitz as Chief Operating Officer from January 1, 2026. This shift to an SE structure, combined with strengthening operational leadership in banking and IT, signals an effort to streamline governance across the group and prepare for the planned...
XTRA:MRK
XTRA:MRKPharmaceuticals

China’s First-in-Class TGCT Drug Approval Might Change The Case For Investing In Merck (XTRA:MRK)

Merck KGaA, Darmstadt, Germany recently reported that China’s NMPA has granted Priority Review approval for pimicotinib, a CSF-1R inhibitor, to treat adult patients with symptomatic tenosynovial giant cell tumor where surgery risks functional limitation or relatively severe morbidity. This first Chemical Drug Class 1 approval in China for TGCT, backed by strong Phase 3 MANEUVER data, adds a differentiated rare-disease therapy to Merck KGaA’s healthcare portfolio in a major market. We’ll now...
XTRA:ALV
XTRA:ALVInsurance

Allianz (XTRA:ALV) Valuation Check As Steady Multi‑Year Returns Meet Conflicting Fair Value Signals

Without a clear single catalyst in focus, Allianz (XTRA:ALV) is drawing attention as investors reassess its recent share performance, income profile, and business scale across insurance and asset management activities. See our latest analysis for Allianz. Allianz’s share price at €387.7 has had a relatively steady few weeks, with a 30 day share price return of 5.73% and a 90 day share price return of 6.42%, while the 1 year total shareholder return of 35.26% and 3 year total shareholder...
XTRA:SAP
XTRA:SAPSoftware

Assessing SAP (XTRA:SAP) Valuation After New Snowflake AI Data Cloud Collaboration

Snowflake partnership sets fresh context for SAP shares SAP (XTRA:SAP) is in focus after announcing a collaboration that links Snowflake’s AI Data Cloud with SAP Business Data Cloud, aiming to simplify data sharing and AI driven insights for enterprise customers. See our latest analysis for SAP. Despite the Snowflake tie up, SAP’s recent 1 day, 7 day and 90 day share price returns of 3.07%, 3.12% and 14.06% declines suggest fading short term momentum. However, its 3 year total shareholder...
XTRA:UZU
XTRA:UZUChemicals

Exploring Three European Small Caps With Promising Potential

The European market has been buoyed by an improving economic backdrop, with the STOXX Europe 600 Index reaching new highs and closing 2025 with its strongest yearly performance since 2021. Against this optimistic landscape, identifying small-cap stocks that exhibit robust fundamentals and growth potential can be particularly rewarding for investors seeking to capitalize on the region's momentum.
XTRA:BAYN
XTRA:BAYNPharmaceuticals

Is Bayer (XTRA:BAYN) Still Attractive After A 94% One Year Share Price Surge?

If you are wondering whether Bayer at around €38.00 is still offering value after a strong run, this article will walk through what the current price actually reflects. Bayer's share price shows a mixed return profile, with a 4.4% move over 7 days, 14.1% over 30 days, 93.6% over 1 year, and longer term returns of a 23.0% decline over 3 years and a 16.0% decline over 5 years. Recent news around Bayer has focused on its ongoing portfolio and restructuring efforts as well as continued attention...
XTRA:ACT
XTRA:ACTChemicals

3 European Stocks Estimated To Be Trading Below Intrinsic Value In January 2026

As the European markets continue to thrive, with the STOXX Europe 600 Index reaching new highs and closing 2025 with impressive gains, investors are increasingly looking for opportunities within this robust economic environment. In such a context, identifying stocks that may be trading below their intrinsic value can provide potential avenues for growth, particularly when these stocks are supported by strong fundamentals and positive market conditions.